Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what discussions she has had with Water UK regarding its warning that the UK does not have sufficient water resources to support planned datacentre expansion.
Answered by Emma Hardy - Minister of State (Department for Environment, Food and Rural Affairs)
WaterUK regularly attends Defra's Water Delivery Taskforce, chaired by the Minister of State for Water and Flooding, Emma Hardy, which brings together Government, regulators and industry and is working to improve the evidence on data centre water use.
Current evidence suggests that existing data centres in England account for just 0.2% of non-household demand. Water companies may refuse a connection to a data centre where sufficient resources are not available. Water companies are responsible for planning and investing to meet future water needs, and Government expects them to continue improving water efficiency and reducing leakage.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what estimate she has made of the water demand of new and planned datacentres, and whether she has made an assessment of the potential risk of their designation as critical national infrastructure taking priority over household water use during drought conditions.
Answered by Emma Hardy - Minister of State (Department for Environment, Food and Rural Affairs)
As the data centre sector grows, Defra is working across Government and with the Environment Agency to better understand this growth and reduce its impact.
Protecting public water supplies for households and businesses remains a priority during periods of acute water stress. Critical national infrastructure status does not create a general obligation on water companies to provide water for cooling. The Security and Emergency Measures Direction requires water companies, when preparing emergency plans, to identify and prioritise vulnerable customers, while also having regard to the needs of non-domestic users and any notified Critical National Infrastructure.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department for Business, Innovation, Science and Trade:
To ask the Secretary of State for Business, Innovation, Science and Trade, what guidance is available to employers on making reasonable adjustments for employees with fluctuating conditions such as endometriosis.
Answered by Kate Dearden - Minister of State (Department for Business, Innovation, Science and Trade)
We are committed to helping working people balance their jobs with their personal lives, including those managing health conditions such as endometriosis. Endometriosis can be classified as a disability, in some cases, under the Equality Act 2010. Where an employee’s symptoms meet the definition, employers may be required to make reasonable adjustments. The Equality and Human Rights Commission has published advice for employers on making reasonable adjustments. Where symptoms are not considered a disability, flexible working can also help people with long-term health conditions thrive at work, allowing employees and employers to agree arrangements that support individual needs alongside work.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department for Education:
To ask the Secretary of State for Education, what assessment her Department has made of the potential impact of endometriosis on school attendance and attainment among girls and young women.
Answered by Paul Waugh - Parliamentary Under-Secretary (Department for Education)
The government recognises that endometriosis can affect a pupil’s health, wellbeing and ability to attend school and participate fully in education. Regular attendance is important for pupils’ attainment, wellbeing and wider development, and schools should work with pupils and families to understand and address health-related barriers to attendance.
Section 100 of the Children and Families Act 2014 places a duty on maintained schools, academies and pupil referral units to make arrangements for supporting pupils with medical conditions, which would include endometriosis. Schools must have regard to the department’s statutory guidance about support for pupils at school with medical conditions, which is available at: https://www.gov.uk/government/publications/supporting-pupils-at-school-with-medical-conditions--3.
This guidance makes clear that pupils with medical conditions should be properly supported so that they can play a full and active role in school life, remain healthy and achieve their academic potential.
The statutory guidance regarding collaboration between schools, academy trusts, governing bodies and local authorities is available at: https://www.gov.uk/government/publications/working-together-to-improve-school-attendance. This guidance promotes a 'support first' approach and expects schools to be particularly mindful of absent pupils because of physical or mental ill health. Schools should work in partnership with families to understand the individual barriers a pupil faces, put appropriate support in place and consider reasonable adjustments where relevant.
In March, the department consulted on revised guidance on supporting children and young people with medical conditions, and this will be published in due course.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department for Education:
To ask the Secretary of State for Education, what guidance her Department provides to schools on recognising and accommodating the impact of endometriosis and related conditions on pupils' education and attendance.
Answered by Paul Waugh - Parliamentary Under-Secretary (Department for Education)
The government recognises that endometriosis can affect a pupil’s health, wellbeing and ability to attend school and participate fully in education. Regular attendance is important for pupils’ attainment, wellbeing and wider development, and schools should work with pupils and families to understand and address health-related barriers to attendance.
Section 100 of the Children and Families Act 2014 places a duty on maintained schools, academies and pupil referral units to make arrangements for supporting pupils with medical conditions, which would include endometriosis. Schools must have regard to the department’s statutory guidance about support for pupils at school with medical conditions, which is available at: https://www.gov.uk/government/publications/supporting-pupils-at-school-with-medical-conditions--3.
This guidance makes clear that pupils with medical conditions should be properly supported so that they can play a full and active role in school life, remain healthy and achieve their academic potential.
The statutory guidance regarding collaboration between schools, academy trusts, governing bodies and local authorities is available at: https://www.gov.uk/government/publications/working-together-to-improve-school-attendance. This guidance promotes a 'support first' approach and expects schools to be particularly mindful of absent pupils because of physical or mental ill health. Schools should work in partnership with families to understand the individual barriers a pupil faces, put appropriate support in place and consider reasonable adjustments where relevant.
In March, the department consulted on revised guidance on supporting children and young people with medical conditions, and this will be published in due course.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has asked NICE to review the position of nabiximols in the treatment pathway for MS-related spasticity, including its use earlier in the pathway.
Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis.
The attached table shows the number of identifiable patients who were prescribed Sativex in the community in England by integrated care board in each financial year from 2023 to 2026 and from April 2026 to June 2026. The NHS Business Services Authority does not hold information on patient condition or reasons for why Sativex has been prescribed.
The Department has made no assessment of the levels of variation in access to Sativex for multiple-sclerosis related spasticity. National Health Service commissioners are expected to take National Institute for Health and Care Excellence (NICE) guidelines fully into account in ensuring that services meet the needs of their local populations. NICE keeps its guidelines under review and would consider the need to update its recommendations on Sativex in light of any new evidence.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure integrated care boards commission nabiximols in line with NICE guideline NG144.
Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis.
The attached table shows the number of identifiable patients who were prescribed Sativex in the community in England by integrated care board in each financial year from 2023 to 2026 and from April 2026 to June 2026. The NHS Business Services Authority does not hold information on patient condition or reasons for why Sativex has been prescribed.
The Department has made no assessment of the levels of variation in access to Sativex for multiple-sclerosis related spasticity. National Health Service commissioners are expected to take National Institute for Health and Care Excellence (NICE) guidelines fully into account in ensuring that services meet the needs of their local populations. NICE keeps its guidelines under review and would consider the need to update its recommendations on Sativex in light of any new evidence.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of trends in the level of regional variation in access to nabiximols for MS-related spasticity since NICE guideline NG144 was published.
Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis.
The attached table shows the number of identifiable patients who were prescribed Sativex in the community in England by integrated care board in each financial year from 2023 to 2026 and from April 2026 to June 2026. The NHS Business Services Authority does not hold information on patient condition or reasons for why Sativex has been prescribed.
The Department has made no assessment of the levels of variation in access to Sativex for multiple-sclerosis related spasticity. National Health Service commissioners are expected to take National Institute for Health and Care Excellence (NICE) guidelines fully into account in ensuring that services meet the needs of their local populations. NICE keeps its guidelines under review and would consider the need to update its recommendations on Sativex in light of any new evidence.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many patients with multiple sclerosis were prescribed nabiximols on the NHS in England in each of the last three years by integrated care board.
Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis.
The attached table shows the number of identifiable patients who were prescribed Sativex in the community in England by integrated care board in each financial year from 2023 to 2026 and from April 2026 to June 2026. The NHS Business Services Authority does not hold information on patient condition or reasons for why Sativex has been prescribed.
The Department has made no assessment of the levels of variation in access to Sativex for multiple-sclerosis related spasticity. National Health Service commissioners are expected to take National Institute for Health and Care Excellence (NICE) guidelines fully into account in ensuring that services meet the needs of their local populations. NICE keeps its guidelines under review and would consider the need to update its recommendations on Sativex in light of any new evidence.
Asked by: Yasmin Qureshi (Labour - Bolton South and Walkden)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to review the current criteria for medical exemption certificates for prescription charges to include endometriosis.
Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)
I refer the Hon Member to the answer provided on 18 August 2026 in response to Question 18253.